HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $85 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Legend Biotech (NASDAQ:LEGN) and maintained an $85 price target.
August 16, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech's stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $85.
The reiteration of a 'Buy' rating and maintenance of an $85 price target by HC Wainwright & Co. indicates a positive outlook for Legend Biotech. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100